Cantor Fitzgerald Estimates Gossamer Bio FY2026 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Gossamer Bio in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer expects that the company will earn ($0.45) per share for the year. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share.

A number of other analysts have also issued reports on GOSS. Wedbush reiterated an "outperform" rating and set a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, May 16th. The Goldman Sachs Group raised their price target on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a report on Friday, May 16th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Tuesday, March 18th.

Gossamer Bio Stock Down 2.4%

NASDAQ GOSS traded down $0.03 during trading hours on Tuesday, hitting $1.24. The company had a trading volume of 1,126,116 shares, compared to its average volume of 1,551,263. The firm's 50 day moving average is $1.06 and its 200 day moving average is $1.05. The company has a market capitalization of $281.85 million, a price-to-earnings ratio of -3.88 and a beta of 1.85. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio has a fifty-two week low of $0.51 and a fifty-two week high of $1.55.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $9.89 million for the quarter, compared to analyst estimates of $3.95 million.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Graham Capital Management L.P. acquired a new stake in shares of Gossamer Bio in the 4th quarter valued at about $32,000. Virtu Financial LLC bought a new stake in Gossamer Bio in the first quarter valued at about $38,000. Fullcircle Wealth LLC acquired a new stake in Gossamer Bio during the fourth quarter valued at approximately $43,000. Invesco Ltd. bought a new position in Gossamer Bio during the 1st quarter worth approximately $48,000. Finally, Velan Capital Investment Management LP acquired a new position in shares of Gossamer Bio in the 4th quarter worth approximately $68,000. 81.23% of the stock is owned by institutional investors and hedge funds.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.